Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Zumedha | Equity Research

Research · Analysis · Insights

Zumedha | Equity Research

Research · Analysis · Insights

  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
Close

Search

Zumedha | Equity Research

Research · Analysis · Insights

Zumedha | Equity Research

Research · Analysis · Insights

  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
Close

Search

Home/EMS Stocks/DCF valuation and investment analysis for Avalon Technologies (NSE: AVALON)as on Mar 2026
EMS Stocks

DCF valuation and investment analysis for Avalon Technologies (NSE: AVALON)as on Mar 2026

By Zumedha Research Team on March 14, 2026 3 Min Read

Here’s a comprehensive DCF valuation and investment analysis for Avalon Technologies (NSE: AVALON) based on the latest available financials.


Key Data Used

Financials (FY25 Actuals):

  • Full year FY25 revenue was ₹1,098 Cr (up 26.6% YoY) and net profit was ₹63.44 Cr (up 126.7% YoY)
  • Q3 FY26 revenue was ₹417.54 Cr and net profit ₹32.60 Cr
  • Current share price: ~₹990 | P/E: ~69x | Market Cap: ~₹6,607 Cr

Growth Guidance & Analyst Estimates:

  • Analysts forecast revenue growth of ~41.9% and profit growth of ~63.4% for FY26
  • Management has guided for 23–25% revenue growth in FY26, with an objective to double FY24 revenues by FY27
  • Prabhudas Lilladher estimates FY25–27 revenue/EBITDA/PAT CAGR of 27.5%/37.7%/45.9% with EBITDA margin expansion of ~170bps

DCF Valuation Model

Assumptions:

ParameterValueRationale
Base Revenue (FY25)₹1,098 CrActual
Base PAT (FY25)₹63.4 CrActual
Revenue CAGR (FY26–28)30%Mgmt guidance + analyst consensus
Revenue CAGR (FY29–30)20%Normalization phase
Terminal Growth Rate8%India EMS sector long-run growth
Net Margin (stabilized)7–8%Expanding from current ~6%
Discount Rate (WACC)14%Indian mid-cap, beta ~1.2
Shares Outstanding~66.8 CrCurrent

Projected Free Cash Flows (₹ Cr):

YearRevenuePAT (~7%)FCF (70% of PAT)
FY26E1,42710070
FY27E1,855148104
FY28E2,412193135
FY29E2,894231162
FY30E3,473277194

Terminal Value (FY30):

  • Terminal FCF: ₹194 Cr
  • Terminal Value = 194 × (1.08) / (0.14 – 0.08) = ₹3,492 Cr
  • PV of Terminal Value (discounted 5 years @ 14%) = ₹1,814 Cr

Sum of PV of FCFs:

YearFCFPV Factor @ 14%PV
FY26700.87761
FY271040.76980
FY281350.67591
FY291620.59296
FY301940.519101
Terminal——1,814
Total Enterprise Value₹2,243 Cr

⚠️ Note: This DCF yields a conservative intrinsic enterprise value. Adding net cash (~₹50 Cr) and dividing by 66.8 Cr shares gives an intrinsic value of ~₹345–380/share on a strict FCF basis. This reflects the reality that Avalon currently converts a low fraction of earnings to free cash flow due to high capex and working capital needs.


Relative / Earnings-Based Valuation (More Market-Relevant)

Given Avalon’s high-growth EMS profile, the market prices it on forward earnings multiples rather than pure DCF:

ScenarioFY27E EPSApplied P/ETarget Price
Bear (30x)~₹2030x₹600
Base (40x)~₹2240x₹880
Bull (50x)~₹2250x₹1,100
Optimistic (55x)~₹2455x₹1,320

Prabhudas Lilladher values the stock at 45x FY27 earnings, arriving at a target of ₹927. The analyst consensus 12-month price target is ₹1,069 with a high estimate of ₹1,328.


Buying Range Assessment

ZonePrice RangeVerdict
🟢 Strong Buy₹650 – ₹750Excellent margin of safety
🟡 Buy₹750 – ₹900Reasonable entry for long-term
🟠 Accumulate₹900 – ₹1,050Fair value; current zone (~₹990)
🔴 Avoid / Wait> ₹1,100Priced for perfection

At the current price of ~₹990, the stock trades near the upper end of fair value on FY27 estimates. It’s not cheap, but not overvalued if management executes on doubling revenues by FY27.


Future Growth & Earnings Potential

Structural Tailwinds:

  • Avalon provides integrated EMS across PCB assemblies, cable/wire harness, sheet metal, aerospace fabrication, magnetics, and system integration — a rare full-stack EMS player in India
  • The company entered the semiconductor equipment manufacturing space, partnering with a leading global semiconductor equipment company, expected to be a significant growth driver
  • The order book jumped 25.4% to ₹1,863 Cr as of September 2025; H1 FY26 revenue surged 48.7% and net profit soared 158%
  • Management targets doubling FY27 revenue again by FY30, driven by new customers in mobility, industrial, and aerospace verticals

Key Risks:

  • EBITDA margins declined slightly to 10.1% in Q2 FY26 from 11% a year ago — margin expansion is needed to justify the valuation
  • High P/E (~69–90x) leaves little room for earnings misses
  • US revenue concentration (~61%) creates tariff/FX risk, though Avalon shares surged 20% on news of an India-US trade deal reducing export tariffs from 50% to 18%
  • Working capital intensity and high capex limit near-term FCF generation

Summary Verdict

MetricValue
Current Price~₹990
DCF Intrinsic Value (conservative FCF)₹345–380
Earnings-Based Fair Value (FY27, 40–45x)₹880–1,000
Analyst Consensus Target₹1,069
Ideal Buy Zone₹650–₹850
RatingACCUMULATE at current levels; BUY on dips below ₹850

Avalon is a genuinely strong India EMS growth story — backed by government PLI tailwinds, a dual-shore model, and entry into high-value segments like semiconductors and defence. But at ~₹990, most of the near-term upside is priced in. Patient investors who can hold 3–5 years may still see significant wealth creation if management delivers on its FY27 and FY30 targets.

This is not financial advice. Please consult a SEBI-registered advisor before making investment decisions.

Author

Zumedha Research Team

Follow Me
Other Articles
Previous

Inox wind Stock Analysis Report Jan 2026

Next

RSI (Relative Strength Index)

Legal Disclaimer Investment Research & Information

Not Investment Advice. All content published on this website — including stock analyses, mutual fund reviews, DCF models, valuation estimates, buying zones, and commentary — is created for our own educational, internal research and informational purposes only. Nothing on this website constitutes financial, investment, legal, or tax advice, nor a solicitation or recommendation to buy, sell, or hold any security or financial instrument.

No Guarantees. It is advised clearly and categorically not o follow these analysis and information blindly for your equity investement purpose as Equity investments and mutual funds are subject to market risks. Past performance is not indicative of future results. All DCF models, fair value estimates, and scenario analyses are based on publicly available data and the author's independent assumptions and may prove materially incorrect. The author/s or owners of this website/portal do not are not liable in whatsoever manner for any positive or negative outcome from your own investment endeavorsYou may lose part or all of your invested capital.

Do Your Own Research. Readers are strongly advised to consult a SEBI-registered investment advisor and conduct their own due diligence before making any investment decision. The author may or may not hold positions in securities discussed on this website.

No Obligations. We, the author/ the publisher/ anybody associated with Zumedha.com does not guarantee the accuracy, adequacy or completeness of any information/data and is not responsible for any errors or omissions or for the results obtained from the use of such information/data. Zumedha.com or anyone involved with zumedha.com will not accept any liability for loss or damage as a result of reliance on the Estimates data. It does not subscribe or endorse any of the services and/or content offered by such third party.

Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
This website is not registered as an Investment Adviser under SEBI (Investment Advisers) Regulations, 2013. All views are personal and for informational purposes only.
© 2026 · All Rights Reserved · For Educational Use Only. RESEARCH · ANALYSIS · INSIGHTS